APEX1 and rectal cancer: The adjusted ORs for the APEX1 Asp/Glu and Glu/Glu genotypes compared with Asp/Asp genotype were statistically significant for colon cancer, but not for rectal cancer (OR 3.04, 95%CI 1.38–6.71, p = 0.006 for colon cancer; OR 1.61, 95%CI 0.64–4.09, p = 0.315 for rectal cancer).